Skip to content

Observational study to collect data on health improvements after mini-invasive operation with Revivent TC device to reshape the heart and reduce its volume

BRAVE-TC: BioVentrix registry assessment of ventricular enhancement for the Revivent TC™ system

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN89757315
Enrollment
100
Registered
2016-11-29
Start date
2016-10-19
Completion date
Unknown
Last updated
2016-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure due to ischemic cardiomyopathy Circulatory System Ischaemic cardiomyopathy

Interventions

Participants receive ventricular reduction as part of their standard care. Prior to the operation, Cardiac Magnetic Resonance or Cardiac Tomography shall be used (according to institutional practice)

Sponsors

BioVentrix, Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients suffering from heart failure symptoms with cardiac dysfunction caused by a previous myocardial infarction resulting in increased ventricular volume and anteroseptal or apical scar Additional general inclusion criteria: 2. Subject is >18 years of age 3. Subject is able and willing to provide written informed consent 4. Subject is on guideline directed medical therapy (GDMT) for heart failure

Exclusion criteria

Exclusion criteria: 1. Inadequate myocardial viability in regions remote from the scar 2. Thrombus or intra-ventricular mass 3. Cardiac Resynchronization Therapy (CRT) 4. Patient intolerance or unwillingness to take anti-coagulation medication 5. Functioning pacemaker leads in antero-apical RV 6. Pulmonary Arterial Pressure > 60 mm Hg 7. Myocardial Infarction less than 90 days before the procedure 8. Previous right neck surgery, previous pericardiotomy, previous left chest surgery that precludes device placement 9. Chronic renal failure with a serum creatinine >2 mg/dL 10. Inoperable coronary disease with significant ischemia 11. Pulmonary disease that would preclude transient single lung ventilation

Design outcomes

Primary

MeasureTime frame
Decrease in Left Ventricular volume is measured using echocardiography at 6 months, 1, 2, 3, 4 and 5 years.

Secondary

MeasureTime frame
Changes in heart failure status assessed by Left Ventricular Ejection Fraction, New York Heart Association class, quality of life assessment, and walking distance as measured by a 6-minute walk exam at baseline, 6 months, 1, 2, 3, 4 and 5 years.

Countries

Czech Republic, Germany, Italy, Switzerland

Contacts

Public ContactNoel Messenger

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026